Literature DB >> 25549933

Association of pre- and post-treatment expectations with improvements after acupuncture in patients with migraine.

Hui Zheng1, Wenjing Huang2, Juan Li1, Qianhua Zheng1, Ying Li1, Xiaorong Chang3, Guojie Sun4, Fanrong Liang1.   

Abstract

OBJECTIVE: To study whether a higher expectation of acupuncture measured at baseline and after acupuncture is associated with better outcome improvements in patients with migraine.
METHODS: We performed a secondary analysis of a previous published trial in which 476 patients with migraine were randomly allocated to three real acupuncture groups and one sham acupuncture control group. All the participants received 20 sessions of acupuncture over a 4-week period. The primary outcome was the number of days with a migraine attack (NDMA) assessed at 5-8 weeks after randomisation. The secondary outcomes were visual analogue scale, headache intensity and quality of life assessed at 4, 8 and 16 weeks after randomisation. Expectations of the acupuncture effect were assessed at baseline and at the end of treatment and categorised into five levels, with 0% the lowest and 100% the highest. Outcome improvement was first compared among the participants with different expectation levels using an analysis of variance model. The association between expectations of treatment and outcome improvement was then calculated using a logistic regression model.
RESULTS: Patients with 100% baseline expectations did not report significantly fewer NDMA than those with 0% baseline expectations after adjusting for the covariates (at 5-8 weeks, 1.7 vs 3.9 days, p=0.987). High baseline expectations had no significant impact on improvement of the primary outcome (100% vs 0%: OR 8.50, 95% CI 0.89 to 191.65, p=0.682). However, patients with 100% post-treatment expectations reported fewer NDMA than those with 0% expectations (primary outcome: 1.3 vs 5.0 days, p<0.001) and were more likely to have a favourable response (100% vs 0%: OR 68.87, 95% CI 6.26 to 1449.73, p=0.002). Similar results were found when analysing the impact of expectation on the secondary outcomes.
CONCLUSIONS: A high level of expectation after acupuncture treatment rather than at baseline was associated with better long-term outcome improvements in patients with migraine. CLINICAL TRIAL NUMBER: NCT00599586. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  ACUPUNCTURE

Mesh:

Year:  2014        PMID: 25549933     DOI: 10.1136/acupmed-2014-010679

Source DB:  PubMed          Journal:  Acupunct Med        ISSN: 0964-5284            Impact factor:   2.267


  4 in total

1.  Efficacy and safety of electroacupuncture in acute decompensated heart failure: a study protocol for a randomized, patient- and assessor-blinded, sham controlled trial.

Authors:  Jungtae Leem; Seung Min Kathy Lee; Jun Hyeong Park; Suji Lee; Hyemoon Chung; Jung Myung Lee; Weon Kim; Sanghoon Lee; Jong Shin Woo
Journal:  BMC Complement Altern Med       Date:  2017-07-11       Impact factor: 3.659

2.  Does patient's expectation benefit acupuncture treatment?: A protocol for systematic review and meta-analysis.

Authors:  Zuoqin Yang; Yan Li; Zihao Zou; Ying Zhao; Wei Zhang; Huiling Jiang; Yujun Hou; Ying Li; Qianhua Zheng
Journal:  Medicine (Baltimore)       Date:  2021-01-08       Impact factor: 1.817

3.  Clinical Studies of Biofield Therapies: Summary, Methodological Challenges, and Recommendations.

Authors:  Shamini Jain; Richard Hammerschlag; Paul Mills; Lorenzo Cohen; Richard Krieger; Cassandra Vieten; Susan Lutgendorf
Journal:  Glob Adv Health Med       Date:  2015-11-01

4.  The long-term effect of acupuncture for patients with chronic tension-type headache: study protocol for a randomized controlled trial.

Authors:  Lingyun Lu; Hui Zheng; Qianhua Zheng; Xinyu Hao; Siyuan Zhou; Shusen Zhang; Tao Wei; Tao Gao; Duoxi Duan; Ling Zhao; Ning Li; Ying Li
Journal:  Trials       Date:  2017-10-03       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.